New Treatment Plan for MAC Infection in HIV Patients
Part of Immune system & allergy, Infections clinical trials.
This study tests an enhanced treatment strategy for MAC (Mycobacterium avium complex), a serious infection that can occur in people with HIV. The trial compares a new approach to standard treatment to see if it works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV infection that has been confirmed by testing
- You have disseminated MAC infection confirmed by culture or molecular testing from a sterile site (like blood or bone marrow)
- You have systemic symptoms consistent with disseminated infection (affecting your whole body)
- You are ready to start standard antimycobacterial therapy and willing to participate
- You can provide written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows HIV patients taking antiretroviral therapy (HIV medications) to understand how well treatment works, especially in people who also have serious infections like tuberculosis, fungal infections, or other opportunistic infections. Researchers will track your health over time to improve treatment outcomes.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
Hear when a new Opportunistic Infections, HIV Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.